Home » US to investigate whether a longer course of Paxlovid is needed to fight reinfections
News

US to investigate whether a longer course of Paxlovid is needed to fight reinfections


Article content

The US National Institutes of Health is in talks with Pfizer Inc to investigate whether a longer course of the antiviral treatment against COVID-19 from drug maker Paxlovid is needed to prevent reinfections, said top US infectious disease expert Dr. Anthony Fauci, Wednesday.

“We’re going to plan what studies we’ll be doing relatively quickly, within the next few days” to determine whether a longer course is needed or not, Fauci said during a White House COVID-19 briefing.

Article content

Rising cases of COVID-19 in the United States are driving the use of therapies, with more than 660,000 courses of Paxlovid pills administered in the country so far.

Some patients have reported that COVID symptoms returned after completing the five-day course of treatment and experienced improvement, but exactly how many experienced such a rebound is unclear.

In Pfizer’s clinical trial, approximately 2% of recipients who received the two-drug treatment saw an increase in viral load after completing the standard course, compared with approximately 1.5% of placebo recipients.

dr. Ashish Jha, White House Covid-19 response coordinator, said data was collected when Delta was the dominant strain of the coronavirus, and it’s unclear whether reinfections are more common in Omicron that now predominates.

Jha said reinfections do not appear to hinder Paxlovid’s ability to reduce hospitalizations and deaths from COVID-19.

Pfizer has suggested that a second five-day course of Paxlovid could treat reinfections. The US Food and Drug Administration said there is currently no evidence to support taking a second five-day course or a 10-day course of the pills.

(Reporting by Michael Erman, editing by Bill Berkrot)

This post US to investigate whether a longer course of Paxlovid is needed to fight reinfections

was original published at “https://financialpost.com/pmn/business-pmn/u-s-to-study-whether-longer-paxlovid-course-needed-to-combat-reinfections”

About the author

admin

Add Comment

Click here to post a comment

Your email address will not be published.